{"id":31256,"date":"2018-10-10T15:52:09","date_gmt":"2018-10-10T15:52:09","guid":{"rendered":"https:\/\/www.upjs.sk\/lekarska-fakulta\/klinika\/root\/iv-interna\/vyskum\/phd\/"},"modified":"2022-11-13T22:07:19","modified_gmt":"2022-11-13T21:07:19","slug":"phd","status":"publish","type":"cpt_klinika","link":"https:\/\/www.upjs.sk\/lekarska-fakulta\/klinika\/iv-interna\/vyskum\/phd\/","title":{"rendered":"Doktorandsk\u00e9 pr\u00e1ce"},"content":{"rendered":"
<\/p>\n
MUDr. Katar\u00edna Demkov\u00e1. Obhajoba 2018. \u0160kolite\u013e prof. MUDr. I. Tk\u00e1\u010d, PhD. MUDr. Ivana Gotthardov\u00e1. Obhajoba 2017. \u0160kolite\u013e prof. MUDr. I. Tk\u00e1\u010d, PhD. MUDr. Zuzana Malachovsk\u00e1. Obhajoba 2017. \u0160kolite\u013e prof. MUDr. I. Tk\u00e1\u010d, PhD. MUDr. M\u00e1ria \u0160tolfov\u00e1, PhD. Obhajoba 2015. \u0160kolite\u013e prof. MUDr. I. Tk\u00e1\u010d, PhD. MUDr. Eva Babjakov\u00e1, PhD. Obhajoba 2015. \u0160kolitelia: prof. MUDr. I. Tk\u00e1\u010d, PhD., prof. MUDr. D. Trejbal, CSc. MUDr. Igor Ga\u013ea, PhD. Obhajoba 2015 MUDr. Eli\u0161ka Fat\u013eov\u00e1. \u0160kolite\u013eka doc. MUDr. E. Szab\u00f3ov\u00e1, PhD. MUDr. Alexandra Lisovszki. \u0160kolite\u013eka doc. MUDr. E. Szab\u00f3ov\u00e1, PhD. MUDr. Anna \u00dcrgeov\u00e1. \u0160kolite\u013e: prof. MUDr. Ivan Tk\u00e1\u010d, PhD..
\nAsoci\u00e1cia vybran\u00fdch g\u00e9nov\u00fdch polymorfizmov so z\u00e1va\u017enos\u0165ou perif\u00e9rneho art\u00e9riov\u00e9ho obliteruj\u00faceho ochorenia u diabetikov 2. typu<\/strong><\/p>\n
\nSledovanie asoci\u00e1ci\u00ed vybran\u00fdch g\u00e9nov\u00fdch polymorfizmov s odpove\u010fou na lie\u010dbu or\u00e1lnymi antidiabetikami glipt\u00ednmi<\/strong><\/p>\n
\nVz\u0165ah vybran\u00fdch g\u00e9nov\u00fdch variantov k prejavom subklinickej ateroskler\u00f3zy na perif\u00e9rnych tepn\u00e1ch<\/strong><\/p>\n
\n\u00da\u010dinok metform\u00ednu v z\u00e1vislosti od genetick\u00e9ho pozadia pacientov s diabetom 2. typu.<\/strong><\/p>\n
\nFarmakogenetick\u00e1 \u0161t\u00fadia s deriv\u00e1tmi sulfonylurey u pacientov s diabetom 2. typu<\/strong><\/p>\n
\nFarmakogenetick\u00e1 \u0161t\u00fadia s metform\u00ednom u pacientov s diabetom 2. typu<\/strong><\/p>\nPrebiehaj\u00face doktorandsk\u00e9 \u0161t\u00fadium<\/h3>\n
\nAsoci\u00e1cia modifikovate\u013en\u00fdch kardiovaskul\u00e1rnych rizikov\u00fdch faktorov so subklinickou ateroskler\u00f3zou<\/strong><\/p>\n
\nPrediktory progresie subklinickej ateroskler\u00f3zy<\/strong><\/p>\n
\nSledovanie efektu lie\u010dby inhib\u00edtormi DPP-4 v z\u00e1vislosti od genotypu<\/strong><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":31253,"menu_order":2,"template":"","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[],"tags":[],"tax_aktuality":[],"class_list":["post-31256","cpt_klinika","type-cpt_klinika","status-publish","hentry"],"acf":{"acf_link_na_externy_obsah":""},"yoast_head":"\n